ESR1 and carcinoma: Our study design focused on two tumor subtypes of BC (HR+/HER2- and HR−/HER2-) and defined cases with ER-rich tumors (more than 10% of the cancer cell nuclei stained) as hormone receptor-positive carcinoma.